Waystar Holding Corp. 2025 Annual Report (10-K) Summary
Business Context and Reporting Period
This filing is the Annual Report on Form 10-K for Waystar Holding Corp. (Nasdaq: WAY) for the fiscal year ended December 31, 2025. Waystar provides AI-powered cloud-based software that simplifies healthcare payments for providers, managing workflows from pre-service eligibility to post-service collection. The company serves over 30,000 clients, including 16 of the top 20 U.S. News Best Hospitals, processing over 7.5 billion transactions annually. The reporting period includes the company's initial public offering (IPO) in June 2024 and the strategic acquisition of Iodine Software Holdings, Inc. in October 2025.
Key Financial Metrics
| Metric | 2025 | 2024 | Change |
|---|---|---|---|
| Total Revenue | $1,099.3 million | $943.5 million | +16.5% |
| Net Income | $112.1 million | ($19.1 million) loss | Turnaround to Profit |
| Adjusted EBITDA | $462.1 million | $383.5 million | +20.5% |
| Adjusted EBITDA Margin | 42.0% | 40.6% | +140 bps |
| Operating Cash Flow | $309.7 million | $169.8 million | +82.0% |
| Net Revenue Retention Rate | 112.0% | 110.1% | +190 bps |
| Total Debt Outstanding | $1.48 billion | $1.24 billion | +19.3% |
| Cash and Cash Equivalents | $61.4 million | $182.1 million | -66.3% |
Material Changes vs. Prior Period
- Profitability Turnaround: The company transitioned from a net loss of $19.1 million in 2024 to net income of $112.1 million in 2025. This was driven by a 101.5% increase in operating income and a 47.8% reduction in interest expense due to debt paydowns and repricing.
- Revenue Growth: Revenue grew 16.5% year-over-year, fueled by a 21.9% increase in subscription revenue and an 11.4% increase in volume-based revenue. Approximately $30 million of the subscription increase and $21.2 million of the volume-based increase were attributed to the Iodine acquisition.
- Acquisition Activity: Waystar acquired Iodine for a total consideration of $1.26 billion ($638.9 million cash and $620.8 million equity) on October 1, 2025. This significantly increased goodwill and intangible assets on the balance sheet.
- Debt Restructuring: The company executed multiple amendments to its First Lien Credit Facility in 2025, including a repricing to 2.00% over SOFR and an increase in the facility size by $250 million. The Second Lien Credit Facility was fully paid down in early 2024.
- Competitor Impact: A cybersecurity incident at a major competitor in February 2024 accelerated Waystar's win rates, generating approximately $11 million in additional revenue in 2025.
Guidance, Outlook, and Risks
Outlook and Strategy: Management expects to continue growing market share through organic expansion and strategic acquisitions. The company is heavily investing in "agentic AI" to move toward an autonomous revenue cycle. The Total Addressable Market (TAM) is estimated at $20 billion in 2025, projected to grow to nearly $25 billion by 2030.
Key Risks and Contingencies:
- Regulatory Environment: The business is subject to complex and evolving healthcare regulations (HIPAA, Anti-Kickback Statute, False Claims Act) and data privacy laws. Changes in reimbursement models or government spending could adversely affect client volumes.
- Debt and Liquidity: With approximately $1.5 billion in outstanding debt, the company faces risks related to interest rate fluctuations and restrictive covenants. While cash flow from operations is strong, significant capital was deployed for the Iodine acquisition.
- Cybersecurity: As a custodian of sensitive healthcare data, the company faces ongoing risks of cyber-attacks, data breaches, and ransomware, which could result in significant liability and reputational damage.
- Integration Risk: Successfully integrating Iodine and future acquisitions is critical to realizing anticipated synergies and revenue growth.
Investor Verification Checklist
- Debt Covenants: Verify compliance with the First Lien Credit Facility leverage ratios and the impact of variable interest rates on future interest expense.
- Acquisition Integration: Monitor the post-acquisition performance of Iodine and the realization of projected synergies in the coming quarters.
- Regulatory Compliance: Review any updates regarding HIPAA enforcement, the No Surprises Act, or state-level data privacy laws that could impact revenue models.
- Customer Concentration: Confirm that the top 10 clients continue to represent a low percentage of total revenue (10.8% in 2025) to assess diversification.
- Stock-Based Compensation: Track the impact of the 2024 Equity Incentive Plan and future grants on non-GAAP net income and cash flow.